Case series of thrombotic thrombocytopenic purpura in children and adolescents.
J. Pediatr. Hematol. Oncol., Apr;25(4):336-9 (2003)
Aseptic meningitis in a child after systemic treatment with high dose cytarabine.
Pediatr. Infect. Dis. J., Jan;20(1):87-9 (2001)
Outcomes for children with gallbladder abnormalities and sickle cell disease.
J. Pediatr., Nov;145(5):617-21 (2004)
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
Cancer Chemother. Pharmacol., Jul;58(1):13-23 (2006)
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.
Clin. Cancer Res., Mar;13(5):1516-22 (2007)
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.
J. Clin. Oncol., Nov;25(31):4922-8 (2007)
Development and validation of a fluorogenic assay to measure separase enzyme activity.
Anal. Biochem., Sep;392(2):133-8 (2009)
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Mol. Cancer Ther., Aug;8(8):2232-42 (2009)
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.
Pediatr Blood Cancer., Jul;54(7):872-8 (2010)
Educational paper. The development of new therapies for pediatric oncology.
Eur. J. Pediatr., May;170(5):555-9 (2011)
Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study.
Clin. Cancer Res., Mar;11(5):1884-9 (2005)
Endogenous knockdown of survivin improves chemotherapeutic response in ALL models.
Leukemia., Feb;26(2):271-9 (2012)